Spots Global Cancer Trial Database for thyroid cancer, papillary
Every month we try and update this database with for thyroid cancer, papillary cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma | NCT02418390 | Thyroid Cancer,... | prophylactic ce... | 20 Years - 70 Years | Seoul National University Hospital | |
| Circulating Biomarkers to Identify Thyroid Cancer | NCT04594720 | Thyroid Cancer Thyroid Cancer,... Benign Thyroid ... | Identification ... Validation grou... | 20 Years - 100 Years | Chang Gung Memorial Hospital | |
| Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients. | NCT05247476 | Thyroid Cancer,... Hypothyroidism | L-T4 L-T4+T3 (thyroi... | 18 Years - 70 Years | Zhongshan Hospital Xiamen University | |
| Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer | NCT06068101 | Thyroid Cancer,... Primary Aldoste... | Secreening test... | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma | NCT02418390 | Thyroid Cancer,... | prophylactic ce... | 20 Years - 70 Years | Seoul National University Hospital | |
| Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer | NCT06068101 | Thyroid Cancer,... Primary Aldoste... | Secreening test... | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort | NCT04396912 | Iatrogenic Hypo... Iatrogenic Hypo... Vocal Cord Para... Vocal Cord Pare... Vocal Cord; Inj... Thyroid Cancer,... Thyroid Cancer Multinodular Go... Thyroid Neoplas... Thyroid Nodule Calcium Deficie... PTH | Total thyroidec... | 17 Years - | Umraniye Education and Research Hospital | |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | NCT03037385 | RET-altered Non... Medullary Thyro... RET-altered Pap... RET-altered Col... RET-altered Sol... Lung Neoplasm Carcinoma, Non-... Thyroid Disease... Thyroid Neoplas... Thyroid Cancer,... Carcinoma, Neur... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Endocrine Syste... Endocrine Gland... Head and Neck N... Adenocarcinoma,... Adenocarcinoma Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neuroendocrine ... Neuroectodermal... Neoplasms, Germ... Neoplasms, Nerv... Colonic Neoplas... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... | pralsetinib (BL... | 18 Years - | Hoffmann-La Roche | |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. | NCT05768178 | Solid Tumor Haematological ... Melanoma Thyroid Cancer,... Ovarian Neoplas... Colorectal Neop... Laryngeal Neopl... Carcinoma, Non-... Glioma Multiple Myelom... Erdheim-Chester... Thyroid Carcino... | Vemurafenib Cobimetinib | 18 Years - | Cancer Research UK | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| Intraoperative Neuromuscular Monitoring and Its Impact on Pre- and Postoperative Acoustic Outcomes in Thyroid Surgery | NCT06254859 | Thyroid Cancer Thyroid Cancer,... | Traditional thy... | - | Fujian Medical University | |
| European Multicenter Study on Surgical Management of Advanced Thyroid Cancer | NCT05796960 | Thyroid Carcino... Thyroid Cancer Thyroid Neoplas... Thyroid Cancer,... Thyroid Cancer,... Thyroid Medulla... Anaplastic Thyr... | Thyroidectomy w... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Leptin Levels in Papillary Thyroid Cancer | NCT01659385 | Thyroid Cancer,... Leptin Levels | 19 Years - 75 Years | University of Nebraska | ||
| A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy | NCT03690388 | Differentiated ... | Cabozantinib Placebo | 16 Years - | Exelixis | |
| More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated | NCT06439745 | Papillary Thyro... Papillary Carci... Thyroid Cancer Thyroid Carcino... Thyroid Cancer,... Lymph Node Meta... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
